Paper40951978
Rates of clinical progression according to biological Alzheimer's disease stages.
Trudel L and 23 others. Alzheimers Dement, 2025. Cited by 9 papers, by iCite.
Cite this record
ConductScience Library. Rates of clinical progression according to biological Alzheimer's disease stages. Papers, record 40951978. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/40951978
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Topics13
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Disease Progression | Major topic |
| Alzheimer Disease | Major topic |
| Cognitive Dysfunction | Major topic |
| Humans | |
| Male | |
| Female | |
| Aged | |
| Positron-Emission Tomography | |
| tau Proteins | |
| Aged, 80 and over | |
| Brain | |
| Cohort Studies | |
| Longitudinal Studies |
Source PubMed
Grants10
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
| Grant, as the record writes it | Agency | Country | NIH project | Stated by | Source |
|---|---|---|---|---|---|
| L60 AG096756 | NIA NIH HHS | United States | L60AG096756 | PubMed | NIH RePORTER |
| Alzheimer's Association | United States | PubMed | PubMed | ||
| P30 AG066530 | NIA NIH HHS | United States | P30AG066530 | PubMed | NIH RePORTER |
| Weston Brain Institute | PubMed | PubMed | |||
| Consortium canadien en neurodégénérescence associée au vieillissement | PubMed | PubMed | |||
| CIHR | Canada | PubMed | PubMed | ||
| Fondation Brain Canada | PubMed | PubMed | |||
| Fonds de Recherche du Québec - Santé | PubMed | PubMed | |||
| P01 AG052350 | NIA NIH HHS | United States | P01AG052350 | PubMed | NIH RePORTER |
| K01 AG083115 | NIA NIH HHS | United States | K01AG083115 | PubMed | NIH RePORTER |
References61
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 38482373 | Predicting functional decline in aging and Alzheimer's disease with PET-based Braak staging. | Brain Commun | 2024 | https://conductscience.org/library/papers/38482373 | PubMed |
| 2 | 22331215 | Performance characteristics of amyloid PET with florbetapir F 18 in patients with alzheimer's disease and cognitively normal subjects. | J Nucl Med | 2012 | https://conductscience.org/library/papers/22331215 | PubMed |
| 3 | 32338734 | Positron Emission Tomography Imaging With [18F]flortaucipir and Postmortem Assessment of Alzheimer Disease Neuropathologic Changes. | JAMA Neurol | 2020 | https://conductscience.org/library/papers/32338734 | PubMed |
| 4 | 36516028 | Tau-PET is superior to phospho-tau when predicting cognitive decline in symptomatic AD patients. | Alzheimers Dement | 2023 | https://conductscience.org/library/papers/36516028 | PubMed |
| 5 | 39500009 | Identification of late-stage tau accumulation using plasma phospho-tau217. | EBioMedicine | 2024 | https://conductscience.org/library/papers/39500009 | PubMed |
| 6 | 26938442 | PET Imaging of Tau Deposition in the Aging Human Brain. | Neuron | 2016 | https://conductscience.org/library/papers/26938442 | PubMed |
| 7 | 40359457 | Validating the Amyloid Cascade Through the Revised Criteria of Alzheimer's Association Workgroup 2024 for Alzheimer Disease. | Neurology | 2025 | https://conductscience.org/library/papers/40359457 | PubMed |
| 8 | 32091549 | Assessment of Demographic, Genetic, and Imaging Variables Associated With Brain Resilience and Cognitive Resilience to Pathological Tau in Patients With Alzheimer Disease. | JAMA Neurol | 2020 | https://conductscience.org/library/papers/32091549 | PubMed |
| 9 | 37321820 | The Use of Tau PET to Stage Alzheimer Disease According to the Braak Staging Framework. | J Nucl Med | 2023 | https://conductscience.org/library/papers/37321820 | PubMed |
| 10 | 31211344 | Associations of Amyloid, Tau, and Neurodegeneration Biomarker Profiles With Rates of Memory Decline Among Individuals Without Dementia. | JAMA | 2019 | https://conductscience.org/library/papers/31211344 | PubMed |
| 11 | 11255443 | Mild cognitive impairment represents early-stage Alzheimer disease. | Arch Neurol | 2001 | https://conductscience.org/library/papers/11255443 | PubMed |
| 12 | 34189247 | The Health & Aging Brain among Latino Elders (HABLE) study methods and participant characteristics. | Alzheimers Dement (Amst) | 2021 | https://conductscience.org/library/papers/34189247 | PubMed |
| 13 | 39740074 | Clinical use of biomarkers in the era of Alzheimer's disease treatments. | Alzheimers Dement | 2025 | https://conductscience.org/library/papers/39740074 | PubMed |
| 14 | 39776249 | Updated appropriate use criteria for amyloid and tau PET: A report from the Alzheimer's Association and Society for Nuclear Medicine and Molecular Imaging Workgroup. | Alzheimers Dement | 2025 | https://conductscience.org/library/papers/39776249 | PubMed |
| 15 | 26194311 | The Alzheimer's Disease Neuroimaging Initiative 2 PET Core: 2015. | Alzheimers Dement | 2015 | https://conductscience.org/library/papers/26194311 | PubMed |
| 16 | 22749065 | Cerebral PET with florbetapir compared with neuropathology at autopsy for detection of neuritic amyloid-β plaques: a prospective cohort study. | Lancet Neurol | 2012 | https://conductscience.org/library/papers/22749065 | PubMed |
| 17 | 27042901 | Mild Cognitive Impairment. | Continuum (Minneap Minn) | 2016 | https://conductscience.org/library/papers/27042901 | PubMed |
| 18 | 31157827 | Association of Amyloid and Tau With Cognition in Preclinical Alzheimer Disease: A Longitudinal Study. | JAMA Neurol | 2019 | https://conductscience.org/library/papers/31157827 | PubMed |
| 19 | 35327650 | Multicenter 18F-PI-2620 PET for In Vivo Braak Staging of Tau Pathology in Alzheimer's Disease. | Biomolecules | 2022 | https://conductscience.org/library/papers/35327650 | PubMed |
| 20 | 40986433 | Implication for Clinical Trials From Longitudinal Tau-PET Accumulation Across Biological Alzheimer Disease Stages. | Neurology | 2025 | https://conductscience.org/library/papers/40986433 | PubMed |
Cited by11
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 9 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42923225 | Noninvasive diagnosis of Alzheimer's disease: a review of emerging biomarkers and multimodal approaches. | Front Cell Dev Biol | 2026 | https://conductscience.org/library/papers/42923225 | PubMed |
| 42889489 | Comparison of brain-derived versus conventional pTau biomarkers in CSF and plasma for detecting Alzheimer's disease. | Brain Commun | 2026 | https://conductscience.org/library/papers/42889489 | PubMed |
| 42557955 | Predicting continuous amyloid PET levels with CSF and plasma brain-derived p-tau217. | Alzheimers Dement | 2026 | https://conductscience.org/library/papers/42557955 | PubMed |
| 42448890 | Using CA1 rather than the whole hippocampus to capture tau-PET Braak stage II. | Eur J Nucl Med Mol Imaging | 2026 | https://conductscience.org/library/papers/42448890 | PubMed |
| 42255958 | Eligibility for anti-amyloid treatment in a multiethnic community-based study. | Alzheimers Dement (Amst) | 2026 | https://conductscience.org/library/papers/42255958 | PubMed |
| 42168643 | Visual versus quantitative tau-PET Braak staging in Alzheimer's disease using [18F]MK6240. | Eur J Nucl Med Mol Imaging | 2026 | https://conductscience.org/library/papers/42168643 | PubMed |
| 41963989 | Continuum of Core 1 biomarkers in preclinical Alzheimer's disease. | Alzheimers Res Ther | 2026 | https://conductscience.org/library/papers/41963989 | PubMed |
| 41667430 | Should all MCI with Alzheimer's biological diagnosis receive anti-amyloid therapy? | Cell Death Dis | 2026 | https://conductscience.org/library/papers/41667430 | PubMed |
| 41556545 | Clinical-biological Alzheimer's disease stage concordance: insights from cohorts and autopsy data. | Brain | 2026 | https://conductscience.org/library/papers/41556545 | PubMed |
| 41266593 | APOE ε4 potentiates tau related reactive astrogliosis assessed by cerebrospinal fluid YKL40 in Alzheimer's disease. | Commun Med (Lond) | 2025 | https://conductscience.org/library/papers/41266593 | PubMed |
| 40951978 | Rates of clinical progression according to biological Alzheimer's disease stages. | Alzheimers Dement | 2025 | https://conductscience.org/library/papers/40951978 | PubMed |
Genes4
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes | Source |
|---|---|---|---|---|
| APP | 351 | PubTator's text mining | https://conductscience.org/library/genes/351 | NCBI Gene |
| MAPT | 4137 | PubTator's text mining | https://conductscience.org/library/genes/4137 | NCBI Gene |
| SNCA | 6622 | PubTator's text mining | https://conductscience.org/library/genes/6622 | NCBI Gene |
| TARDBP | 23435 | PubTator's text mining | https://conductscience.org/library/genes/23435 | NCBI Gene |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Trials
- Comments and corrections
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/40951978
GET https://conductscience.org/api/papers/v1/40951978/authors?page=2